You are here: Industry Insights > MS

News List

Scientists Discover How the 'Mono' Virus Might Trigger MS drugs.com
January 26, 2022
A one-two punch from science has clearly tagged the mononucleosis virus, Epstein-Barr, as a major cause of multiple sclerosis.
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers EuropeanPharmaceuticalReview
October 28, 2021
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.
Biogen announces results from Phase IIIb NOVA study for MS europeanpharmaceuticalreview
August 06, 2021
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
On World Brain Day Join WFN, MSIF to Stop Multiple Sclerosis prnasia
July 20, 2021
On July 22, the World Federation of Neurology (WFN) and MS International Federation (MSIF) are leading the global World Brain Day campaign to raise awareness for multiple sclerosis (MS).
First Signs of MS May Often Go Undiagnosed drugs
June 28, 2021
Early symptoms of multiple sclerosis may commonly be missed for years before the right diagnosis is made, a new study suggests.
Novartis reveals long-term results for MS therapy Kesimpta pharmatimes
June 24, 2021
Novartis has revealed new long-term data for its B-cell targeting therapy Kesimpta, showing that mean immunoglobulin G (IgG) and immunoglobulin M (IgM) were preserved in adults with relapsing multiple sclerosis (MS) receiving the therapy over 3.5 years.
InFlectis BioScience Licenses Rights to a Potential New Class of Therapies for Demyelinating Diseases from The University of Chicago firstwordpharma
June 23, 2021
InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment of demyelinating diseases.
EC approves Ponvory for relapsing MS pharmatimes
May 26, 2021
The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
UK NICE rejects NHS use of ozanimod for MS treatment pharmaceutical-technology
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has decided not to recommend ozanimod for the treatment of relapsing multiple sclerosis (MS) patients on National Health Service (NHS) in England and Wales.
UK launch for progressive multiple sclerosis mega-trial pharmatimes
May 08, 2021
The MS Society had announced that a world-first mega-trial for progressive multiple sclerosis (MS) will be launched in the UK later this year.

Previous page 1 2 3 4 5 6 7 8 9 Next page